Abstract
The Transforming Growth Factor (TGF)-β-Smad signaling pathway regulates diverse biological processes essential for normal development and homeostasis. The Smad-interacting transcriptional modulator SnoN and its related homologs have emerged as important modulators of TGF-β signaling and responses. SnoN forms a physical complex with the TGF-β-regulated Smad2/Smad3 and co-Smad4 proteins and either represses or stimulates TGF-β-induced Smad-dependent transcription in a cell- and promoter-specific manner. In addition, the TGF-β-activated Smads recruit several ubiquitin ligases to SnoN and thereby promote the ubiquitination and consequent degradation of SnoN. Additional modifications of SnoN, including sumoylation, may contribute to the regulation of SnoN function and its role in TGF-β signaling. Collectively, these studies suggest that SnoN function is intimately linked to the TGF-β-Smad pathway in cellular signaling. Although the mechanisms by which SnoN modulates signaling in the TGF-β-Smad pathway are beginning to be characterized, the full range of SnoN functions and underlying mechanisms in normal development and disease processes remains to be elucidated.
Keywords: SnoN, Ski, TGF-β, Smad, signaling, transcription control, cell cycle, cancer
Current Molecular Medicine
Title: SnoN in TGF-β Signaling and Cancer Biology
Volume: 8 Issue: 4
Author(s): Isabelle Pot and Shirin Bonni
Affiliation:
Keywords: SnoN, Ski, TGF-β, Smad, signaling, transcription control, cell cycle, cancer
Abstract: The Transforming Growth Factor (TGF)-β-Smad signaling pathway regulates diverse biological processes essential for normal development and homeostasis. The Smad-interacting transcriptional modulator SnoN and its related homologs have emerged as important modulators of TGF-β signaling and responses. SnoN forms a physical complex with the TGF-β-regulated Smad2/Smad3 and co-Smad4 proteins and either represses or stimulates TGF-β-induced Smad-dependent transcription in a cell- and promoter-specific manner. In addition, the TGF-β-activated Smads recruit several ubiquitin ligases to SnoN and thereby promote the ubiquitination and consequent degradation of SnoN. Additional modifications of SnoN, including sumoylation, may contribute to the regulation of SnoN function and its role in TGF-β signaling. Collectively, these studies suggest that SnoN function is intimately linked to the TGF-β-Smad pathway in cellular signaling. Although the mechanisms by which SnoN modulates signaling in the TGF-β-Smad pathway are beginning to be characterized, the full range of SnoN functions and underlying mechanisms in normal development and disease processes remains to be elucidated.
Export Options
About this article
Cite this article as:
Pot Isabelle and Bonni Shirin, SnoN in TGF-β Signaling and Cancer Biology, Current Molecular Medicine 2008; 8 (4) . https://dx.doi.org/10.2174/156652408784533797
DOI https://dx.doi.org/10.2174/156652408784533797 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Synthesis, Evaluation and Molecular Docking Studies of 1,3,4-oxadiazole- 2-thiol Incorporating Fatty Acid Moiety as Antitumor and Antimicrobial Agents
Letters in Drug Design & Discovery Monoclonal Antibodies: A Prospective and Retrospective View
Current Medicinal Chemistry Targeting the Resistance of Pancreatic Cancer Cells to Nutrient Deprivation: Anti-Austerity Compounds
Current Drug Delivery Antisense Strategies
Current Molecular Medicine Current Advances in the Synthesis and Antitumoral Activity of SIRT1-2 Inhibitors by Modulation of p53 and Pro-Apoptotic Proteins
Current Medicinal Chemistry New Insights into Redox-Modulated Cell Signaling
Current Pharmaceutical Design Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Current Cancer Drug Targets Breast Cancer: A Review of Risk Factors and New Insights into Treatment
Current Cancer Therapy Reviews Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Clinical Relevance of Cytokines and Inflammatory Molecules in Rheumatoid Vasculitis
Current Rheumatology Reviews Effects of Nanosuspension Formulations on Transport, Pharmacokinetics, In Vivo Targeting and Efficacy for Poorly Water-soluble Drugs
Current Pharmaceutical Design Alpha-Terpineol as Antitumor Candidate in Pre-Clinical Studies
Anti-Cancer Agents in Medicinal Chemistry Prognostic and Predictive Molecular Markers in Cutaneous Malignant Melanoma: The First Step Toward Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Local Treatment for Lymphoid Malignancies of the Eye
Anti-Cancer Agents in Medicinal Chemistry Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells
Current Molecular Medicine The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Pixuvri<sup>®</sup> (Pixantrone Dimaleate, BBR 2778): From Lab to Market
Current Organic Chemistry Polyphenols and Cardiovascular Disease: A Critical Summary of the Evidence
Mini-Reviews in Medicinal Chemistry